Posted by Michael Wonder on 03 Sep 2020
Janssen disappointed with second NICE no for Spravato
3 September 2020 - Janssen says it is disappointed with second draft guidance from the National Institute for Health and Care Excellence (NICE) rejecting NHS funds for its nasal depression spray Spravato (esketamine).
Following a second appraisal consultation, the Institute is not recommending use of the spray, in combination with a selective serotonin re-uptake inhibitor or serotonin and norepinephrine re-uptake inhibitor, for adults living with treatment-resistant major depressive disorder who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.
